 MENLO PARK, Calif., Sept. 08, 2021 GLOBE NEWSWIRE -- CohBar, Inc. NASDAQ: CWBR, a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend healthy lifespan, today announced the United States Patent and Trademark Office has granted a patent, U.S. No. 11,111,271, covering CohBars lead candidate CB4211 and related compositions, as well as methods of treatment, including methods of treating nonalcoholic steatohepatitis NASH. 